Experts talk about the impact of a collaborative and supportive patient-provider relationship in the management of IBS-C and CIC.
Amy Ladewski, PA-C
Advertisement
Articles by Amy Ladewski, PA-C
Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.
Experts discuss the current use of OTC and review guidelines for prescription treatments for IBS-C and CIC.
Thought leaders review prevalence, common symptoms, and patient burden of IBS-C and CIC.
Advertisement
Latest Updated Articles
The Importance of the Patient-Provider RelationshipPublished: December 17th 2024 | Updated:
- IBS-C and CIC Overview
Published: December 17th 2024 | Updated:
- Premature Treatment Discontinuation (Time to Response)
Published: December 17th 2024 | Updated:
- Over-the-Counter and Prescription Treatment Guidelines and Use
Published: December 17th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
2
Menopause: A Constellation of Syndromes Across 13 Body Systems
3
Menopause Education Lags in Residency Training Across Primary Care Specialties
4
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
5
